NR 565 Advanced Pharmacology
Fundamentals Midterm Comprehensive
Examination 2026/2027 | Verified
Questions
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles, Pharmacokinetics, and Prescribing
Guidelines
Question 1. Which process describes the movement of a drug from the site of
administration into the systemic circulation?
A. Metabolism
B. Absorption
C. Excretion
D. Distribution
Rationale: Absorption is the process by which a drug enters the bloodstream from
its site of administration. It is influenced by route, formulation, pH, and blood
flow.
Question 2. Bioavailability refers to:
A. The fraction of an administered dose that reaches systemic circulation in
unchanged form
B. The rate of drug metabolism only
C. The volume of distribution exclusively
D. The half-life of the drug
Rationale: Bioavailability is the proportion of the administered dose that reaches
the systemic circulation intact. Intravenous administration yields 100%
bioavailability by definition.
Question 3. First-pass metabolism primarily affects drugs administered by which
route?
A. Intravenous
B. Oral
C. Sublingual
,D. Transdermal
Rationale: Orally administered drugs are absorbed from the gastrointestinal tract
and pass through the liver via the portal circulation before reaching systemic
blood, allowing substantial hepatic metabolism.
Question 4. The volume of distribution (Vd) is best described as:
A. A theoretical volume relating the amount of drug in the body to the
measured plasma concentration
B. The actual anatomic volume of plasma
C. Only the volume of extracellular fluid
D. The volume of urine produced per day
Rationale: Vd is a proportionality constant that relates total amount of drug in the
body to plasma concentration. A large Vd suggests extensive tissue distribution.
Question 5. Drug clearance is defined as:
A. The volume of plasma cleared of drug per unit time
B. The amount of drug metabolized by the liver
C. The time required for half the drug to be eliminated
D. The fraction of drug bound to plasma proteins
Rationale: Clearance (CL) is the volume of plasma from which a drug is
completely removed per unit time. It determines the maintenance dose required to
achieve a target steady-state concentration.
Question 6. Which parameter best predicts the time required for a drug to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Rationale: Steady state is reached after approximately four to five half-lives
regardless of dose or infusion rate. Elimination half-life is therefore the primary
determinant of time to steady state.
Question 7. A patient with hepatic impairment is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic principle most
accurately guides dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
,D. Switch to an intravenous formulation only if creatinine clearance falls below 30
mL/min
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral
bioavailability of high-extraction drugs. Therefore the dose must be decreased to
avoid toxicity. This principle is foundational in advanced pharmacokinetics for
nurse prescribers.
Question 8. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic synthesis of albumin increases
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of
highly protein-bound drugs. The unbound concentration drives pharmacologic
effect and toxicity risk, requiring careful monitoring.
Question 9. Which cytochrome P450 enzyme is responsible for the majority of
clinically significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
Rationale: CYP3A4 is involved in the metabolism of more than 50% of all
prescription medications. It is highly susceptible to inhibition and induction,
making it the most common source of clinically significant drug interactions.
Question 10. A patient is prescribed a drug with a narrow therapeutic index.
Which monitoring strategy is most appropriate?
A. Routine monitoring of serum drug levels to ensure they remain within the
therapeutic range
B. Administering the drug only when symptoms are severe
C. Using the standard dose without monitoring, as it is usually safe
D. Monitoring only for adverse effects, not serum levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Routine serum level monitoring is essential to prevent
toxicity or subtherapeutic failure.
, Question 11. What is the primary purpose of a loading dose?
A. To maintain steady-state plasma concentrations
B. To rapidly achieve therapeutic plasma concentrations
C. To reduce the risk of adverse effects
D. To prolong the elimination half-life of the drug
Rationale: A loading dose is administered to rapidly reach the therapeutic range,
bypassing the time it would take to reach steady state through maintenance dosing
alone.
Question 12. Which of the following describes a drug that is a competitive
antagonist?
A. It binds to the receptor and activates it.
B. It binds to the receptor and blocks the action of an agonist, but can be
overcome by increasing the agonist concentration.
C. It binds irreversibly to the receptor and permanently inactivates it.
D. It binds to an allosteric site and enhances the agonist effect.
Rationale: A competitive antagonist competes with the agonist for the same
binding site. Its effects can be overcome by increasing the concentration of the
agonist.
Question 13. A patient with renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What is the most appropriate initial dose
adjustment?
A. Decrease the dose or increase the dosing interval.
B. Increase the dose to compensate for loss of renal function.
C. Maintain the usual dose but monitor closely.
D. Administer a loading dose only.
Rationale: Renal impairment reduces the clearance of drugs excreted unchanged
by the kidneys, leading to accumulation and toxicity. Dose reduction or interval
extension is necessary.
Question 14. What is the definition of bioavailability?
A. The amount of drug metabolized by the liver
B. The fraction of an administered dose that reaches the systemic circulation
unchanged
C. The volume of plasma cleared of drug per unit time
D. The time it takes for half of the drug to be eliminated
Rationale: Bioavailability (F) represents the extent and rate at which the active
Fundamentals Midterm Comprehensive
Examination 2026/2027 | Verified
Questions
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles, Pharmacokinetics, and Prescribing
Guidelines
Question 1. Which process describes the movement of a drug from the site of
administration into the systemic circulation?
A. Metabolism
B. Absorption
C. Excretion
D. Distribution
Rationale: Absorption is the process by which a drug enters the bloodstream from
its site of administration. It is influenced by route, formulation, pH, and blood
flow.
Question 2. Bioavailability refers to:
A. The fraction of an administered dose that reaches systemic circulation in
unchanged form
B. The rate of drug metabolism only
C. The volume of distribution exclusively
D. The half-life of the drug
Rationale: Bioavailability is the proportion of the administered dose that reaches
the systemic circulation intact. Intravenous administration yields 100%
bioavailability by definition.
Question 3. First-pass metabolism primarily affects drugs administered by which
route?
A. Intravenous
B. Oral
C. Sublingual
,D. Transdermal
Rationale: Orally administered drugs are absorbed from the gastrointestinal tract
and pass through the liver via the portal circulation before reaching systemic
blood, allowing substantial hepatic metabolism.
Question 4. The volume of distribution (Vd) is best described as:
A. A theoretical volume relating the amount of drug in the body to the
measured plasma concentration
B. The actual anatomic volume of plasma
C. Only the volume of extracellular fluid
D. The volume of urine produced per day
Rationale: Vd is a proportionality constant that relates total amount of drug in the
body to plasma concentration. A large Vd suggests extensive tissue distribution.
Question 5. Drug clearance is defined as:
A. The volume of plasma cleared of drug per unit time
B. The amount of drug metabolized by the liver
C. The time required for half the drug to be eliminated
D. The fraction of drug bound to plasma proteins
Rationale: Clearance (CL) is the volume of plasma from which a drug is
completely removed per unit time. It determines the maintenance dose required to
achieve a target steady-state concentration.
Question 6. Which parameter best predicts the time required for a drug to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Rationale: Steady state is reached after approximately four to five half-lives
regardless of dose or infusion rate. Elimination half-life is therefore the primary
determinant of time to steady state.
Question 7. A patient with hepatic impairment is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic principle most
accurately guides dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
,D. Switch to an intravenous formulation only if creatinine clearance falls below 30
mL/min
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral
bioavailability of high-extraction drugs. Therefore the dose must be decreased to
avoid toxicity. This principle is foundational in advanced pharmacokinetics for
nurse prescribers.
Question 8. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic synthesis of albumin increases
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of
highly protein-bound drugs. The unbound concentration drives pharmacologic
effect and toxicity risk, requiring careful monitoring.
Question 9. Which cytochrome P450 enzyme is responsible for the majority of
clinically significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
Rationale: CYP3A4 is involved in the metabolism of more than 50% of all
prescription medications. It is highly susceptible to inhibition and induction,
making it the most common source of clinically significant drug interactions.
Question 10. A patient is prescribed a drug with a narrow therapeutic index.
Which monitoring strategy is most appropriate?
A. Routine monitoring of serum drug levels to ensure they remain within the
therapeutic range
B. Administering the drug only when symptoms are severe
C. Using the standard dose without monitoring, as it is usually safe
D. Monitoring only for adverse effects, not serum levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Routine serum level monitoring is essential to prevent
toxicity or subtherapeutic failure.
, Question 11. What is the primary purpose of a loading dose?
A. To maintain steady-state plasma concentrations
B. To rapidly achieve therapeutic plasma concentrations
C. To reduce the risk of adverse effects
D. To prolong the elimination half-life of the drug
Rationale: A loading dose is administered to rapidly reach the therapeutic range,
bypassing the time it would take to reach steady state through maintenance dosing
alone.
Question 12. Which of the following describes a drug that is a competitive
antagonist?
A. It binds to the receptor and activates it.
B. It binds to the receptor and blocks the action of an agonist, but can be
overcome by increasing the agonist concentration.
C. It binds irreversibly to the receptor and permanently inactivates it.
D. It binds to an allosteric site and enhances the agonist effect.
Rationale: A competitive antagonist competes with the agonist for the same
binding site. Its effects can be overcome by increasing the concentration of the
agonist.
Question 13. A patient with renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What is the most appropriate initial dose
adjustment?
A. Decrease the dose or increase the dosing interval.
B. Increase the dose to compensate for loss of renal function.
C. Maintain the usual dose but monitor closely.
D. Administer a loading dose only.
Rationale: Renal impairment reduces the clearance of drugs excreted unchanged
by the kidneys, leading to accumulation and toxicity. Dose reduction or interval
extension is necessary.
Question 14. What is the definition of bioavailability?
A. The amount of drug metabolized by the liver
B. The fraction of an administered dose that reaches the systemic circulation
unchanged
C. The volume of plasma cleared of drug per unit time
D. The time it takes for half of the drug to be eliminated
Rationale: Bioavailability (F) represents the extent and rate at which the active
